Tovecimig's BLA submission in 2L biliary tract cancer tests whether ORR and PFS gains survive FDA scrutiny without a clean OS signal

Bull

FDA accepts the BLA and grants accelerated approval on the basis of the confirmed ORR of 17.1% vs 5.3% (p=0.031) and the striking PFS hazard ratio of 0.44, treating these as reasonably likely to predict clinical benefit in an orphan indication with no approved second-line standard of care. The crossover-confounded OS data is acknowledged as uninformative rather than negative, and the post-hoc pooled OS analysis (9.8 vs 6.1 months) provides supportive context that satisfies reviewers, opening a commercially addressable rare oncology market with orphan drug exclusivity.

Bear

FDA issues a refuse-to-file or issues a complete response letter on the grounds that ORR of 17.1% in a small randomized trial (n=111 tovecimig arm) is insufficient for regular approval and that the OS data — ITT HR of 1.05 with a p-value of 0.78 — actively undermines clinical benefit claims regardless of crossover confounding; the agency may require a confirmatory OS-powered trial before granting any approval pathway, which would substantially delay and dilute the thesis.